DALLAS, Jan. 15, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Antigenics Inc. (Nasdaq:AGEN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/AGEN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Antigenics Inc. (AGEN) researches and develops drug therapies for the treatment of cancers and infectious diseases. The Company's lead drug therapeutic, Oncophage (R), is an adjuvant for the treatment of kidney cancer, currently approved in Russia. The Company's QS-21 is currently under development with partners for 15 clinical-stage vaccines. Four of these vaccines are in phase III clinical trials for the treatment of non-small cell lung cancer, melanoma and malaria. The Company also has two drug therapy products in phase I, including a liposomal platinum chemotherapeutic drug, called Aroplatin (TM), and a genital herpes vaccine.
In the report, the analyst notes:
"The Company stated in its latest 10-Q that working capital requirements appear to be adequate to fund operations though at least 2010, and likely well into 2011. Funds will be derived from anticipated revenue as well as licensing proceeds from collaborations and supply agreements.
"In October 2008, the Company said it had submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for approval to market Oncophage in Europe for earlier-stage kidney cancer. The Company reported on October 20 that the EMEA is expected to reject its initial application at this time. Further options are under discussion at the Company to ascertain its best next step in the European market."
To read the entire report visit: http://www.beaconequity.com/i/AGEN
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.